BioSniper
Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment W

January 30, 2027
Company
BeOne Medicines Ltd. (ONC)
Drug
maintenance
Indication
Ovarian Cancer

Other upcoming events for ONC

Phase 1 StartPhase 1 Start: A Phase 1, Single-dose, Open-label, Randomized, Crossover Study in Healthy Adult Participants to Eva
Jun 18, 2026
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy and Safety of
Mar 31, 2027
Phase 3 ReadoutPhase 3 Topline: A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy a
Oct 1, 2027
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Either Cisplatin or C
Oct 21, 2027
Phase 3 ReadoutPhase 3 Topline: An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus
Oct 31, 2027

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
ONC OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle